Molecular Partners AG annual cash and equivalents
2019
2020
2021
2022
2023
2024
2025
Molecular Partners AG Cash & Equivalents Growth & History (MOLN)
Molecular Partners AG's cash and equivalents was CHF82.7M for fiscal 2025.
View full Molecular Partners AG company overviewMolecular Partners AG annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | CHF82.7M | CHF18.8M | +29.40% |
| 2024 | 2024-12-31 | CHF63.9M | −CHF3.4M | −5.10% |
| 2023 | 2023-12-31 | CHF67.3M | −CHF20.6M | −23.47% |
| 2022 | 2022-12-31 | CHF87.9M | CHF16.1M | +22.47% |
| 2021 | 2021-12-31 | CHF71.8M | −CHF61.9M | −46.30% |
| 2020 | 2020-12-31 | CHF133.7M | CHF58.0M | +76.62% |
| 2019 | 2019-12-31 | CHF75.7M | — | — |
Molecular Partners AG quarterly cash and equivalents
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | CHF67.9M | −CHF14.0M | −17.13% |
| Q1 2026 | 2026-03-31 | CHF64.3M | −CHF17.1M | −21.04% |
| Q4 2025 | 2025-12-31 | CHF82.7M | CHF18.8M | +29.40% |
| Q3 2025 | 2025-09-30 | CHF82.4M | — | — |
| Q2 2025 | 2025-06-30 | CHF82.0M | CHF17.9M | +27.96% |
| Q1 2025 | 2025-03-31 | CHF81.4M | — | — |
| Q4 2024 | 2024-12-31 | CHF63.9M | −CHF3.4M | −5.10% |
| Q2 2024 | 2024-06-30 | CHF64.1M | CHF820,000 | +1.30% |
| Q4 2023 | 2023-12-31 | CHF67.3M | −CHF20.6M | −23.47% |
| Q2 2023 | 2023-06-30 | CHF63.2M | −CHF51.7M | −44.98% |
| Q4 2022 | 2022-12-31 | CHF87.9M | CHF16.1M | +22.47% |
| Q2 2022 | 2022-06-30 | CHF114.9M | — | — |
| Q4 2021 | 2021-12-31 | CHF71.8M | — | — |
Molecular Partners AG cash and equivalents trends
Over the last five fiscal years, Molecular Partners AG's cash and equivalents decreased from CHF133.7M to CHF82.7M, a change of −CHF51.1M. The latest reported quarter, Q2 2026, shows CHF67.9M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Molecular Partners AG source filings ↗